Catheter Precision (NYSEAMERICAN:VTAK) Posts Earnings Results, Beats Expectations By $19.51 EPS

Catheter Precision (NYSEAMERICAN:VTAK) posted its earnings results on Monday. The company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51, FiscalAI reports. The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.60 million. Catheter Precision had a negative return on equity of 114.26% and a negative net margin of 2,044.08%.

Catheter Precision Price Performance

NYSEAMERICAN:VTAK opened at $0.83 on Tuesday. The company has a current ratio of 0.10, a quick ratio of 0.08 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.23 million, a P/E ratio of -0.04 and a beta of -1.04. Catheter Precision has a 12 month low of $0.76 and a 12 month high of $15.68. The business’s 50-day moving average is $1.07 and its 200 day moving average is $1.67.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent quarter. 20.34% of the stock is currently owned by hedge funds and other institutional investors.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.